ELVN vs ENGN: fair value comparison
Enliven Therapeutics, Inc. and enGene Holdings Inc. · Updated 2026-10-19
ELVN has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. ENGN has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, ELVN currently ranks higher by quality score.
| ELVN | ENGN | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $37.32 | $1.67 |
| 12-month range | $15.14–$61.15 | $1.44–$12.17 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #237 of 301 Healthcare | #238 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The lower-middle quarter | The bottom quarter |
Full single-stock breakdowns: ELVN fair value analysis · ENGN fair value analysis